Related Experiment Videos
The mortality risk associated with digitalis treatment after myocardial infarction
Insights
Digitalis therapy in patients surviving acute myocardial infarction was linked to a higher mortality risk. This study suggests caution when prescribing digitalis to post-heart attack patients.
Area of Science:
- Cardiology
- Clinical Research
- Pharmacology
Background:
- Acute myocardial infarction (AMI) survivors face long-term mortality risks.
- Digitalis is a medication sometimes used in heart conditions.
- The impact of digitalis on post-AMI mortality requires careful evaluation.
Purpose of the Study:
- To investigate the association between digitalis therapy and mortality in patients after surviving an acute myocardial infarction.
- To determine the long-term effects of digitalis on postinfarction survival rates.
Main Methods:
- A cohort of 867 patients who survived AMI were followed for 24-48 months.
- Survival analysis using the Cox regression model was performed on 728 patients.
- Statistical adjustments were made for clinical imbalances and significant covariates.
Main Results:
- 16.7% of patients died during follow-up.
- Digitalis-treated patients were older, had more cardiac risk factors, and exhibited higher mortality.
- Digitalis therapy was associated with a significantly increased postinfarction mortality risk (RR 2.3, p < 0.001) after adjustment.
Conclusions:
- Digitalis therapy is associated with a significantly increased risk of mortality in patients post-myocardial infarction.
- Caution is advised when considering digitalis treatment for patients who have experienced a heart attack.
- Further research may be warranted to explore alternative therapies or refine digitalis usage in this population.
Abstract:
We examined the effects of digitalis therapy on postinfarction mortality throughout a 24-month to 48-month follow-up in 867 patients who survived an acute myocardial infarction. During follow-up, 145 patients died (16.7% mortality). At the time of hospital discharge, 31% of the patients were taking digitalis. The digitalis-treated patients were older, had more medical-cardiac risk factors, and had a higher mortality rate throughout the follow-up than the nondigitalis-treated patients. Statistical techniques were used to adjust for clinical imbalances between the digitalis-treated patients and nondigitalis-treated patients. The survival analysis (n = 728 patients) utilized the Cox regression model, and the digitalis-associated mortality risk was identified only after all significant covariates were allowed, so that mortality could be predicted as accurately as possible. Digitalis therapy was associated with a significantly increased postinfarction mortality risk after adjustment for the predictor covariates (relative risk 2.3, 95% confidence interval 1.4-3.7, p less than 0.001). The findings from this large multicenter study suggest that it would be prudent to exercise caution in the use of digitalis in postinfarction patients.